Recent Stock Performance and Business Scale

United Therapeutics (UTHR) has drawn investor attention after recent trading, with the stock last closing at US$545.96 and showing mixed short term moves, including a decline over the past month and a gain over the past 3 months.

The company reports annual revenue of US$3.17b and net income of US$1.29b, primarily from its pharmaceuticals segment, with most sales generated in the United States and a smaller contribution from international markets.

At the current share price of US$545.96, the stock has seen a 9.91% year to date share price return and a 92.68% total shareholder return over one year. This indicates notable longer term momentum alongside some softer recent trading.

If United Therapeutics has you looking more closely at healthcare and AI in medicine, it could be worth scanning other opportunities through our 40 healthcare AI stocks

Those returns come alongside an intrinsic value estimate that sits below the current US$545.96 share price and a higher price target. This leaves a clear tension: is United Therapeutics undervalued, or is future growth already priced in?

Most Popular Narrative: 17.9% Undervalued

United Therapeutics most followed valuation narrative pegs fair value at about $665.23 per share, compared with the last close at $545.96. This sets up a clear valuation gap for investors to weigh.

The company's innovation wave pipeline, including studies in progressive fibrosis, next-generation delivery platforms (oral, implantable), and organ manufacturing (xenotransplant/3D printing), positions United Therapeutics to benefit from the expanding focus on personalized and regenerative medicine. These areas can create new revenue streams and margin expansion opportunities as these long-horizon technologies approach clinical milestones and eventual commercialization.

Want to see what is baked into that valuation gap? Revenue stepping up, margins holding firm, and a future earnings multiple that quietly does the heavy lifting. Curious which specific growth path and profitability mix underpin that $665.23 figure, and how long the narrative assumes the current pulmonary franchise can carry the story? The full narrative lays out those numbers in black and white so you can test them against your own view.

Result: Fair Value of $665.23 (UNDERVALUED)

However, there is still real execution risk, particularly if key trials stumble or competition in pulmonary hypertension and IPF pressures pricing and future cash flow expectations.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

With the mixed sentiment in this story, it helps to stress test the numbers yourself and decide how much upside or risk you see. To understand what is currently exciting some investors about United Therapeutics, review the 4 key rewards

Looking for more investment ideas?

If United Therapeutics is on your radar, do not stop there. The real edge often comes from comparing it with other stocks that fit clear, focused criteria.

• Target reliable cash generators by scanning companies with strong balance sheets and solid fundamentals using the solid balance sheet and fundamentals stocks screener (48 results).
• Spot potential mispricings by reviewing companies that screen as high quality yet potentially overlooked through the 44 high quality undervalued stocks.
• Build your watchlist with companies that combine quality with the potential to fly under most investors' radars via the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.